-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target

Benzinga·09/14/2026 11:03:46
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.